HOPA 2026 Complete Bundle On-Demand

UAN#: 0465-0000-26-006-H01-P

Presenter:

• Mary Walters, PharmD, BCOP - Director Pharmacy Precision Medicine

Session Description:

This program prepares oncology pharmacists to interpret tumor molecular profiling, emphasizing tumor-agnostic indications. Participants will learn a stepwise approach to recommending personalized therapies by analyzing test features, evaluating variant significance, and applying results to each patient's clinical context.

Learning Objectives:

1. Define the role of tumor agnostic therapies in Precision Oncology
2. Assess the characteristics of biomarker tests
3. Evaluate the clinical significance of a tumor agnostic biomarker
4. Contextualize tumor-agnostic biomarker results to individualized therapeutic plans

UAN#: 0465-0000-26-012-H99-P

Presenter:

• Samantha Maples, PharmD, BCOP - Clinical Pharmacy Specialist Supervisor

Session Description:

Post-transplant lymphoproliferative disorder (PTLD) is a serious, and oftentimes malignant, complication of both solid organ and stem cell transplants. Early recognition and prompt intervention are imperative due to the high mortality associated with PTLD. Traditionally, treatment options have been limited; however, new treatments are emerging that may add additional options for PTLD treatment.

Learning Objectives:

1. Recall the epidemiology and risk factors associated with the development of PTLD
2. Identify common clinical manifestations of PTLD and summarize general treatment principles
3. Select the optimal treatment regimen based on patient and PTLD disease characteristics
4. Discuss novel therapies being studied for PTLD treatment

UAN#: 0465-0000-26-014-H03-P

Presenters:

• Jake Beechy, JD, MBA - Vice President
• Marco Martino, PharmD, BCOP, BCPS, JD, MBA - Healthcare Consultant
• Anthony Trovato, PharmD, BCPS, MS, 340B ACE - 340B Program Pharmacist

Session Description:

The 340B Drug Pricing Program was signed into law in 1992, but there have been numerous changes and challenges to the 340B Drug Pricing Program recently. There have been numerous pharmaceutical manufacturers enacting additional requirements for Covered Entities to access medications. There are also numerous ongoing litigation cases in the Courts, States passing laws in response to manufacturers' actions, and the Federal legislature proposing legislation directly affecting the 340B Drug Pricing Program. This session will discuss all of the recent and ongoing updates to the 340B Drug Pricing Program, potential future updates to the 340B Drug Pricing Program, and how stakeholders can respond to ensure that their Covered Entity is providing the best care for its patients, while still maintaining compliance.

Learning Objectives:

1. Discuss how the 340B Drug Pricing Program has evolved since its enaction in 1992
2. List the ways recent actions by pharmaceutical manufacturers and subsequent litigation have changed and affected the 340B Drug Pricing Program
3. List the ways that States and the Federal government are responding to changes in the 340B Drug Pricing Program via active and pending legislation
4. Demonstrate how best to respond to changes in the 340B Drug Pricing Program while maintaining compliance

UAN#: 0465-0000-26-016-H01-P

Presenters:

• Sara deHoll, PharmD, BCOP - Clinical Pharmacist, Neuro-Oncology and Hematology
• Kelly Fritz, PharmD, BCOP - Clinical Pharmacist and Adjunct Assistant Professor

Session Description:

As cancer patients are living longer, more individuals are developing either intracranial metastases or leptomeningeal disease. Even with these devastating diagnoses, therapies exist to improve overall survival and enhance quality of life. This session will review the current challenges and evidence-based recommendations for the treatment of both intracranial and leptomeningeal metastases from solid tumors. The focus will be on the application of targeted therapies and the assessment of their potential to penetrate the blood-brain barrier, as well as a discussion of current recommendations for intrathecal therapies. The presentation will address the operational challenges associated with drug administration and insurance authorization for these treatment options. Finally, non-pharmacologic interventions, such as radiation therapy, surgical approaches, and supportive care strategies, will be discussed.

Learning Objectives:

1. Identify the most common solid tumor types with a predisposition for central nervous system (CNS) involvement and describe the typical clinical manifestations associated with CNS metastases
2. Evaluate current pharmacologic treatment strategies for managing CNS metastases, including potential sequence and combination with non-pharmacologic treatments
3. Explain the therapeutic roles of systemic and intrathecal therapies in leptomeningeal disease, including considerations for drug selection, dosing, and administration
4. Summarize the interdisciplinary approach to managing CNS metastases in solid tumors with a focus on supportive care

UAN#: 0465-0000-26-018-H01-P

Presenters:

• Megan Frankie Duperreault, PharmD, BCOP - Hematology Pharmacist

Session Description:

Immune thrombocytopenia (ITP) is a diagnosis of exclusion, mediated by a complex autoimmune syndrome contributing to increased morbidity and mortality if refractory to front-line therapies. Recently the novel BTK inhibitor, rilzabrutinib, joined the armamentarium for ITP-directed therapy. In this session we will evaluate the FDA-approved ITP treatments.

Learning Objectives:

1. Outline the pathogenesis and clinical presentation of immune thrombocytopenia (ITP)
2. Recognize the manifestations of ITP and complications of its treatment
3. Evaluate safety and efficacy outcomes for the management of ITP
4. Design a treatment plan for a patient with chronic ITP

UAN#: 0465-0000-26-020-H04-P

Presenters:

• Binni Kunvarjee, PharmD, BCOP - Clinical Pharmacy Specialist
• Houry Leblebjian, PharmD, BCOP, DPLA - Senior Clinical Pharmacy Manager
• Lisa Modelevsky, PharmD, BCOP - Clinical Pharmacy Manager, Residency Program Director

Session Description:

Pharmacy residency preceptors are instrumental in the development of future clinical pharmacists, however, their leadership roles within residency programs are often undefined and underutilized. While the Residency Program Director (RPD) role is well-established, other leadership opportunities such as Residency Program Coordinator (RPC) and advisors lack standardization across professional organizations and institutions. This session will explore the current landscape of preceptor leadership, identify gaps in formal role development, and propose structured pathways to expand on and recognize leadership opportunities for preceptors. Additionally, this session will highlight strategies to formally recognize and reward preceptors for their accomplishments in leadership roles, promoting continued engagement and professional growth.

Learning Objectives:

1. Define the current landscape of leadership roles for preceptors in residency programs
2. Identify opportunities to expand preceptor leadership
3. Propose a framework for leadership pathways for preceptors
4. Demonstrate the value of leadership development for preceptors and programs

UAN#: 0465-0000-26-022-H01-P

Presenters:

• Brooke Adams, PharmD, BCOP - Clinical Pharmacy Specialist
• Emilie Aschenbrenner, PharmD, BCOP - Hematology Clinical Coordinator
• Megan May, PharmD, BCOP, FHOPA, FAPO - Clinical Oncology Pharmacy Specialist
• Donald Moore, PharmD, BCOP, FCCP, FASHP - Clinical Oncology Pharmacy Manager

Session Description:

Bispecific T-cell engagers (BTCEs) represent a new and rapidly expanding drug class, with their use expected to increase as indications continue to expand. However, barriers such as treatment-related adverse events, and other logistical considerations have limited their widespread use especially in community-based setting. To optimize the patient outcomes with BTCEs, we have developed this bootcamp for oncology pharmacists to ensure all pharmacists no matter their practice site are empowered to care for patients on these therapies. This bootcamp will discuss best practices for toxicity management, explore implementation strategies for a variety of healthcare settings, and end with an expert-led panel discussion highlighting the key insights and lessons learned from real-world experience.

Learning Objectives:

1. Review the adverse events profiles of bispecific T-cell engagers (BTCE)
2. Discuss multidisciplinary strategies for the monitoring, mitigation, and management of adverse events associated with BTCEs
3. Evaluate strategies to enhance interdisciplinary collaboration and coordination among healthcare systems
4. Describe approaches used by institutions to support BTCE formulary decisions and financial considerations
5. Demonstrate how oncology pharmacists contribute to the development, operationalization, and integration of BTCEs in various healthcare practice settings
6. Identify patient selection criteria to optimize BTCE administration
7. Analyze infrastructure strategies within diverse health-system settings that prepare clinical staff, patients, and caregivers through education and support to enhance the safe use of BTCEs in the outpatient setting

UAN#: 0465-0000-26-007-H01-P

Presenters:

• Benjamin Lee, PharmD, BCOP, BCPS - Clinical Pharmacy Specialist, Lymphoma/Myeloma/CART
• Brian Primeaux, PharmD, BCOP - Clinical Pharmacy Manager, Lymphoma/Myeloma/CART

Session Description:

There have been many changes in the management of newly-diagnosed and relapsed/refractory Hodgkin Lymphoma (HL). The addition of Nivolumab-AVD, Brentuximab vedotin (BV)-AVD, and BrECADD as preferred regimens and the introduction of PET-adapted treatment has changed the treatment landscape of newly-diagnosed Stage III-IV HL. For the relapsed/refractory setting, the addition of immune checkpoint inhibitors and antibody-drug conjugates have added additional treatment options for patients who would have otherwise received traditional chemotherapy (GVD or ICE alone).

This session will discuss pivotal trial data associated with novel combinations in all lines of therapy for HL and how to apply this data clinically to therapy selection for patients. Additionally, the implementation of PET-adapted therapy in late stage newly-diagnosed patients will be explored.

Learning Objectives:

1. Describe the clinical presentation and pathological features of classical Hodgkin Lymphoma (cHL)
2. Analyze pivotal clinical trial data for novel treatment strategies in newly-diagnosed, advanced stage cHL
3. Select the appropriate initial therapy for a patient with newly-diagnosed, advanced stage cHL
4. Design a therapy plan for a patient with newly-diagnosed, advanced stage cHL based on interim PET results
5. Evaluate clinical trial data on targeted agents in relapsed/refractory cHL

UAN#: 0465-0000-26-024-H99-P

Presenters:

• Rachel Feaster, PharmD, BCOP, BCPS - Clinical Oncology Pharmacist
• Christy Harris, PharmD, BCOP - Associate Professor of Pharmacy Practice

Session Description:

As interest in non-traditional cancer therapies grows, oncology pharmacists increasingly encounter patients using or inquiring about controversial treatments such as ivermectin, fenbendazole, and mebendazole. These repurposed drugs are often promoted through social media or anecdotal reports, despite limited or conflicting clinical evidence. This 1-hour continuing education session will provide an overview of the current data surrounding these agents, discuss ethical and safety concerns, and examine their potential for drug interactions or other clinical considerations. Participants will also explore communication strategies that support respectful, patient-centered dialogue - balancing scientific integrity with empathy and trust-building. By the end of the session, attendees will be better equipped to evaluate the risks and benefits of these therapies and guide oncology patients through informed decision-making.

Learning Objectives:

1. Describe misinformation related to the use of controversial therapies in oncology, including repurposed drugs such as ivermectin, fenbendazole, and mebendazole
2. Evaluate the current evidence regarding efficacy and clinical relevance of selected controversial therapies
3. Identify potential risks and ethical concerns related to the use of non-evidence-based treatments in oncology care
4. Apply effective, patient-centered communication strategies to discuss controversial therapies while promoting informed, evidence-based decision making

UAN#: 0465-0000-26-010-H05-P

Presenters:

• Nic Mastascusa, PharmD, BCNP - Associate Professor
• Kellie Weddle, PharmD, BCOP, FCCP, FHOPA - Clinical Professor

Session Description:

In this session, we will conduct a brief review of theranostics, including a brief discussion of currently available therapeutic radiopharmaceuticals. We will highlight specific issues related to the safe and effective use of these agents. A snapshot of drug development in this space will also be discussed. This will be followed by an interactive presentation of clinical examples of the use of theranostic agents, including discussions around introducing radiopharmaceuticals in the clinical care plan. We will evaluate the impact on patient clinical outcomes, how to identify, minimize, and treat adverse events related to these agents and assure safety to the patients, caregivers, and healthcare providers.

Learning Objectives:

1. Identify key concepts related to the use of radioactive materials for theranostic applications
2. Recall current FDA approved radiopharmaceuticals (RP) and provide an overview of the RP pipeline
3. Analyze case-based examples of patients eligible for RP therapy
4. Interpret patient specific parameters and evaluate patient outcomes when considering RP therapy
5. Illustrate ways to implement RP into clinical practice

UAN#: 0465-0000-26-026-H01-P

Presenters:

• Lauren Garner, PharmD, BCPPS, CPP - Clinical Pharmacist Practitioner
• Kynlon Phillips, PharmD, BCOP, BCPS, CPP - Clinical Pharmacist Practitioner

Session Description:

Over the last few years, two new medications (mirdametinib and tovorafenib) have been approved for use in pediatric solid tumors targeting the BRAF/MEK pathway. Additionally, older agents such as trametinib and dabrafenib, which were previously developed, have recently been approved for use in pediatric solid tumors. These approvals include novel, pediatric-friendly formulations that facilitate administration and have contributed to increased utilization in this patient population. Each of these agents has slight differences in mechanism of action, approved indication, available formulations and adverse effect profiles. This session will provide an overview of these new agents and formulations and their use in the pediatric population.

Learning Objectives:

1. Evaluate recent literature exploring the use of selumetinib and trametinib/dabrafenib in pediatric solid tumors
2. Discuss key clinical trials leading to the approval of mirdametinib and tovorafenib in the pediatric population
3. Identify available dosage forms of BRAF/MEK pathway inhibitors and associated administration challenges in the pediatric population
4. Develop strategies to monitor and manage adverse effects of BRAF/MEK pathway inhibitors in pediatric patients

UAN#: 0465-0000-26-028-H99-P

Presenters:

• Elyse MacDonald, PharmD, MS, BCPS, FASHP - Director of Pharmacy Services
• Jennifer Murphy, PharmD, BCOP - Senior Pharmacist in the Cancer Center Investigational Drug Service

Session Description:

This engaging and innovative session will lead the audience through a thought-provoking approach to evaluating their current research pharmacy practices and how to invite process improvement into their respective workplace and across the institutional enterprise. The speakers will highlight implementation strategies and best practices for start-up, life-cycle management, accountability, regulatory compliance, metrics, financial health/budgets, and technology along with a call to action for pharmacists to strengthen clinical trial conduct at their sites.

Learning Objectives:

1. Identify the common challenges faced in pharmacy operations during clinical trials
2. Apply best practices and innovative strategies that can enhance the efficiency of pharmacy operations in clinical trials
3. Develop strategies to effectively navigate and overcome challenges in implementing site efficiencies in clinical trials
4. Illustrate the role of the research pharmacy workforce to advocate for site workflows, growth, implementation, and challenges across the site/enterprise

UAN#: 0465-0000-26-032-H01-P

Presenters:

• Jason Ernstberger, PharmD, BCOP - Clinical Pharmacist, Malignant Hematology and Cellular Therapies
• Brooke Peters, PharmD, BCOP - Associate Director of Pharmacy

Session Description:

This session will provide an in-depth review of menin inhibitors with a focus on FDA-approved therapy for relapsed/refractory KMT2A-rearranged or NPM1 mutated acute myeloid leukemia (AML). Attendees will gain clinical insights into the use of menin inhibitors, including dosing considerations, adverse event management, and patient selection. The presentation will also evaluate ongoing clinical trials for emerging menin inhibitors, highlighting potential roles in therapy for KMT2A- and NPM1-mutated AML.

Learning Objectives:

1. Analyze the prognostic significance and treatment implications of KMT2Ar and NPM1m in AML
2. Apply key clinical pearls and evidence-based management of adverse effects to optimize menin inhibitor therapy
3. Appraise the clinical impact of literature leading to the FDA approval of ziftomenib and revumenib
4. Evaluate safety and efficacy data on agents in the menin inhibitor pipeline

UAN#: 0465-0000-26-034-H01-P

Presenters:

• Jeremy Pappacena, PharmD, BCOP - Clinical Pharmacy Specialist

Session Description:

Gastric and esophageal cancers have notoriously been challenging malignancies to treat. Since 2023, we have seen reports of numerous trials attempting to improve outcomes in the early- and late-stage settings. This session will review several key trials to help guide patient selection for various treatment regimens.

Learning Objectives:

1. Analyze recent updates in the management of gastric and esophageal cancers
2. Describe the mechanistic differences of newer therapies in late-stage gastric and esophageal cancer treatment
3. Create an appropriate supportive care plan for gastric cancer patients receiving zolbetuximab
4. Utilize primary literature to select an appropriate treatment regimen for gastric and esophageal cancer patients in the early- and late-stage settings

UAN#: 0465-0000-26-036-H99-P

Presenters:

• Ryan Beechinor, PharmD, BCOP, BCPS - Clinical Specialist, Hematology/Oncology

Session Description:

Pharmacists completing residency often have foundational research experience but face new challenges sustaining scholarly activity in independent practice. This session offers practical strategies to help early-career oncology pharmacists initiate and complete meaningful research during their early career years. Drawing on national guidance, published data, and personal insights, we will explore common barriers - such as limited time, lack of mentorship, and research design uncertainty - and provide tactical solutions to overcome them. Topics include publishing residency projects, identifying feasible research questions, building mentorship and physician collaborations, leveraging institutional resources, and staying accountable. Attendees will leave with a toolkit to navigate institutional expectations, define SMART goals, and successfully disseminate their work. Whether you're aiming to grow your CV, advance clinical practice, or pursue grant-funded opportunities, this session empowers early-career oncology pharmacists to embed scholarship into their professional identity and contribute meaningfully to the future of evidence-based cancer care.

Learning Objectives:

1. List common challenges or barriers that oncology pharmacists may encounter when engaging in research post-residency
2. Identify at least two available resources that can improve the efficiency of research project development and manuscript construction

UAN#: 0465-0000-26-038-H01-P

Presenter:

• Annalise Labatut, PharmD, BCOP - Oncology Clinical Pharmacy Specialist

Session Description:

This breakout session aims to empower oncology pharmacists to utilize updates in the practice guidelines and clinical data to individualize therapy for patients with hormone receptor-positive metastatic breast cancer whose diseases have progressed on a first-line CDK4/6 inhibitor. The session will review recent clinical trial data and guideline updates, including the use of subsequent CDK4/6 inhibitors, targeted therapy, and an antibody-drug conjugate, as well as clinical pearls to support shared decision-making with patients and the multidisciplinary team. A case-based discussion will illustrate practical application of the presented data.

Learning Objectives:

1. Review updates in the practice guidelines and clinical data for second-line therapy for patients with hormone-receptor positive metastatic breast cancer
2. Choose an appropriate treatment plan for a patient with hormone-receptor positive metastatic breast cancer in the second-line setting

UAN#: 0465-0000-26-040-H01-P

Presenters:

• Cassandra Rush, PharmD, BCOP - Advanced Patient Care Pharmacist, Hematology/Oncology/Bone Marrow Transplant

Session Description:

Remestemcel-L (Ryoncil®) was FDA approved on December 18, 2024 for the treatment of steroid refractory acute graft versus host disease (SR-aGVHD) in pediatric patients 2 months to 17 years old. The first in class therapy comes at a high cost - $194,000 per infusion (wholesale acquisition cost), with a median of 10 doses per patient treatment course ($1,940,000). This session will review the current data available on efficacy and safety remestemcel-L and discuss its place in therapy for SR-aGVHD.

Learning Objectives:

1. Summarize study data that led to the FDA approval of remestemcel-L for pediatric steroid refractory acute graft versus host disease
2. Discuss place in therapy for remestemcel-L in relation to other therapies for graft versus host disease and the impact cost of treatment may have on use

UAN#: 0465-0000-26-042-H99-P

Presenter:

• Courtney Morris, PharmD, BCPS - Pharmacy Program Coordinator

Session Description:

Preceptors and residents alike often wonder about the efficacy of feedback, particularly when it can be tough to give or receive it. A commonly utilized paradigm for these tricky situations is the feedback sandwich. While this provides format to frame challenging feedback in a way that feels deliverable, it can also fall apart or be hard to swallow. This session explores delivering uncomfortable feedback by looking at the intentions of the feedback sandwich and challenging its traditional use. Alternative feedback formats that encourage more direct, empathetic, and actionable strategies - fostering kind and honest communication that is foundational to professional growth - will be discussed.

Learning Objectives:

1. Describe the use of behavioral psychology, communication theory, and coaching framework to deliver direct, empathetic, and actionable feedback in uncomfortable situations
2. Present feedback that is timely, specific, and supportive utilizing one of the shared methods

UAN#: 0465-0000-26-044-H01-P

Presenter:

• Katie O'Reilly, PharmD, BCOP - Oncology Clinical Pharmacy Specialist

Session Description:

Small cell lung cancer (SCLC) is an aggressive cancer that typically responds to platinum-etoposide treatment in both the limited and extensive stage. Most patients will experience relapse or progression so advancements in treatment options for SCLC are needed. This session will review updates in treatment options for both limited and extensive stage SCLC. This includes exploring the use of immunotherapy in limited stage small cell lung cancer as a maintenance treatment option. It will also discuss practice-changing literature in extensive stage including bispecific T-cell engager (BiTE) therapy and the addition of Lurbinectedin to maintenance atezolizumab.

Learning Objectives:

1. Discuss the role of immunotherapy in limited stage small-cell lung cancer (LS-SCLC)
2. Interpret the current data regarding recent small-cell lung cancer (SCLC) treatment updates

UAN#: 0465-0000-26-046-H01-P

Presenter:

• Alexandra Wolff, PharmD, BCOP - Clinical Pharmacy Specialist

Session Description:

Gene therapy is transforming the landscape of hematology and oncology, offering curative potential for inherited disorders. This session provides a practical primer for pharmacists on the fundamentals of gene therapy, with a focus on comparing in vivo and ex vivo approaches. Attendees will learn key differences in mechanisms, delivery platforms, and clinical applications, using sickle cell disease and hemophilia as case examples. The session will highlight operational, safety, and access challenges unique to each method, equipping pharmacists to support gene therapy implementation and patient care. Join us to demystify gene therapy and gain actionable insights for the evolving role of pharmacists in this rapidly advancing field.

Learning Objectives:

1. Describe the fundamental differences between in vivo and ex vivo gene therapy approaches, including mechanisms of action and delivery platforms
2. Explain the clinical applications, benefits, and challenges of in vivo versus ex vivo gene therapy using current examples in hematology and oncology

UAN#: 0465-0000-26-030-H01-P

Presenters:

• Andrew Kowalski, PharmD, BCOP - Multiple Myeloma Clinical Pharmacist
• Jordan Snyder, PharmD, BCOP - Clinical Hematology Pharmacist

Session Description:

Quadruplet induction regimens, CAR-T cell therapies and bispecific antibodies are changing the treatment landscape of multiple myeloma from new diagnosis through late relapse. This BCOP session will address quadruplet induction therapy for newly diagnosed myeloma and the shifting role of autologous stem cell transplant in consolidation. Attendees will also gain valuable insight into the emergence of CAR-T in early relapse and the appropriate sequencing of bispecific antibodies, CAR-T, and many other options. Grab your ruby slippers because we're not in Kansas anymore.

Learning Objectives:

1. Describe the data supporting quadruplet therapy in transplant eligible and transplant ineligible newly diagnosed multiple myeloma
2. Evaluate the paradigm of autologous stem cell transplant for multiple myeloma in the context of newer therapeutic options
3. Compare the use of CAR-T to established combination therapies in the setting of early relapse in multiple myeloma
4. Examine the use of bispecific T-cell engagers in relapsed/refractory multiple myeloma
5. Create a treatment plan for a patient with relapsed/refractory multiple myeloma based on available data sequencing therapies

UAN#: 0465-0000-26-048-H01-P

Presenters:

• Lisa Holle, PharmD, BCOP, FHOPA, FISOPP - Associate Professor (CHS)
• Katie Morgan, PharmD, BCOP, CPP - GU MSL
• Rowena Schwartz, PharmD, BCOP, FHOPA - Professor of Pharmacy Practice

Session Description:

Non-clear cell renal cell carcinoma (nccRCC) represents a diverse and underrepresented group of kidney cancers that account for approximately 20-25% of all RCC cases. Unlike clear cell RCC, nccRCC subtypes exhibit distinct molecular characteristics, clinical behaviors, and therapeutic responses. Despite recent progress in RCC treatment, patients with nccRCC continue to face limited evidence-based options, as most landmark trials exclude these variants.

This interactive panel discussion will explore emerging treatment strategies, subtype-specific approaches, and ongoing clinical trials and share their perspective on how this information is best used in daily practice for these less common tumors. Attendees will gain a deeper understanding of current patient management challenges, molecular targets, and novel therapies aimed at improving outcomes in this heterogeneous disease group.

Learning Objectives:

1. Identify the major histological subtypes of non-clear cell renal carcinoma (nccRCC) and their clinical implications
2. Evaluate current and emerging therapeutic strategies for treating nccRCC including targeted therapy, immunotherapy, and combination approaches
3. Discuss the challenges in clinical trial design and drug development for rare RCC subtypes
4. Formulate a treatment strategy for a patient newly diagnosed nccRCC

UAN#: 0465-0000-26-049-H99-P

Presenters:

• Edna Cheung, PharmD, BCOP - Inpatient Hematology/Oncology Clinical Pharmacist
• Adam DiPippo, PharmD, BCOP - Clinical Pharmacy Specialist, Leukemia & Coordinator, PGY2 Oncology Pharmacy Residency
• Lesley Volz, PharmD, BCOP, DPLA - Oncology Pharmacy Residency Program Director

Session Description:

The learning environment has changed drastically in the past 5 years, with the COVID-19 pandemic and significant technological advances. Because most of today's oncology pharmacy learners identify as Gen Z (generation Z, born between 1997 and 2012), there is an increasingly pronounced generation gap between oncology pharmacy learners and preceptors. A shift in learning styles, personal values, and the burgeoning amount of information to learn in hematology/oncology presents new challenges for preceptors. The recruitment and selection process must also consider the evolving generational differences in values and communication styles. This interactive session aims to empower preceptors and residency programs to adapt effective techniques for teaching oncology pharmacy learners and recruiting PGY2 Oncology residents in the Gen Z era.

Learning Objectives:

1. Describe characteristics of Gen Z, including communication styles, professional priorities, and learning preferences
2. Assess the impact of implicit bias during residency interviews and candidate selection
3. Explain strategies for residency program leadership to streamline and modernize the recruitment process
4. Implement innovative teaching techniques and modalities to effectively precept Gen Z oncology pharmacy learners

UAN#: 0465-0000-26-076-H01-P

Impact of BCMA and GPRC5D Polymorphisms on Response to Bispecific Antibodies Targeting BCMA and GPRC5D

Presenter:

• Issam Hamadeh, PharmD, BCOP, BCPS - Clinical Pharmacy Specialist

Session Description:

The therapeutic landscape of multiple myeloma has witnessed dramatic changes over the past few decades because of our deeper understanding of disease biology. This culminated in introduction of novel agents that have improved patient outcomes such as T-cell engaging bispecific antibodies (T-BsAbs). Despite unprecedented response rates of 60-70%, there is a proportion of patients who do not derive any clinical benefit. Defining underlying mechanisms of resistance to these agents is a topic of great interest; however, ongoing research is geared towards elucidating patterns of resistance at time of relapse. The primary objective of this research project is to uncover the molecular determinants of response by interrogating impact of polymorphisms in BCMA and GPRC5D as well as their downstream signaling pathways.

Learning Objectives:

1. Define the frequencies in single nucleotide polymorphisms in candidate genes (BCMA, GPRC5D, TRAF3, MAP3K, NFKB) in specimens collected from peripheral blood vs those from bone marrow
2. Describe the impact of polymorphisms in candidate genes (BCMA, GPRC5D, TRAF3, MAP3K, NFKB) on response to T-cell engaging bispecific antibodies

Pharmacogenomic Effects on High-Dose Methotrexate Clearance in Patients with Diffuse Large B-cell Lympohoma

Presenter:

• Jordan Lundberg, PharmD, BCOP - Clinical Specialist Pharmacist

Session Description:

High-dose methotrexate (HDMTX) is an integral component in the treatment of many cancers, including diffuse large B-cell lymphoma. Numerous enzymes and transport proteins are involved in methotrexate (MTX) clearance. Genes encoding these enzymes and transport proteins include SLCO1B1, SLCO1B3, SLC22A6, SLC22A8, ABCB1, ABCG2, ABCC2, and ABCC4. There is currently no standard of care (SOC) for pharmacogenomics testing for adult lymphoma patients scheduled to receive HDMTX. Given the increased availability and broad range of single nucleotide polymorphisms (SNPs) tested in the current genotyping arrays, we plan to comprehensively evaluate SNPs involved in HDMTX pharmacokinetics. We seek to identify SNPs significantly associated with delayed HDMTX clearance and toxicity to develop a more personalized approach to the administration of HDMTX.

Learning Objectives:

1. Describe single nucleotide polymorphisms (SNPs) associated with high-dose methotrexate pharmacokinetics
2. Summarize SNPs associated with increased toxicity from high-dose methotrexate

UAN#: 0465-0000-26-051-H01-P

Presenters:

• Emma Jones, PharmD, BCOP - Genitourinary Clinical Oncology Specialist
• Jordan McPherson, PharmD, BCOP, MS - Oncology Pharmacy Manager

Session Description:

This session will guide pharmacists through the evolving landscape of steroid-refractory immune-related adverse events (irAEs). Focusing on high-risk toxicities - colitis, pneumonitis, hepatitis, and myocarditis - experts will review pathophysiology, treatment escalation, and emerging therapies. This presentation will also briefly address management of less common irAEs. Attendees will explore current limited literature, consensus guideline updates, and ongoing clinical trials. Clinical cases will highlight logistical hurdles in initiating secondary immunosuppressants and coordinating subspecialty care. A blend of lecture and interactive discussion will provide practical insights to support early recognition, timely escalation, and optimal immunosuppressive selection for steroid-refractory irAEs.

Learning Objectives:

1. Review the fundamentals of steroid-refractory immune-related adverse event management
2. Describe the irAEs that commonly and uncommonly present as steroid-refractory
3. Identify agents utilized in the management of steroid-refractory irAEs
4. Evaluate notable recent literature on steroid-refractory irAE management
5. Apply principles of steroid-refractory irAE management to guide treatment in patient cases

UAN#: 0465-0000-26-055-H01-P

Presenter:

• Rebecca Gonzalez, PharmD, BCOP, FASTCT - Clinical Pharmacist Specialist, Blood and Marrow Transplantation/Cellular Immunotherapy

Session Description:

Hematology patients receiving chimeric antigen receptor therapy (CAR-T) can experience toxicities due to off-tumor binding resulting in a deleterious systemic inflammatory cascade driving these unique novel events. This session will offer an in-depth exploration of the incidence and mechanisms beyond cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), focusing on immune effector cell-associated toxicities including enterocolitis (IEC-EC) and hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). It will additionally expand on rare toxicities including delayed neurological events including cranial nerve palsy's (CNP) and other movement and neurocognitive toxicities (MNT) as well as second primary malignancies (SPMs). Exploration of evidence-based monitoring protocols, including review of early clinical manifestations, predictive laboratory markers as well as comprehensive management strategies will be discussed to mitigate off-tumor risks, as well as optimize safety and therapeutic outcomes.

Learning Objectives:

1. Describe the spectrum of emerging off-tumor toxicities in patients treated with chimeric antigen receptor therapy (CAR-T)
2. Summarize incidence of off-tumor toxicities in pivotal trials and real word literature
3. Identify clinical manifestations indicative of these unique adverse effects for early recognition and intervention
4. Formulate evidence-based monitoring and treatment protocols to mitigate off-tumor side effects of CAR-T

UAN#: 0465-0000-26-057-H01-P

Presenters:

• Kelly Gable, PharmD, BCPP, FAAPP - Professor and Director of Well-being and Resilience
• Amy Indorf, PharmD, BCOP - Clinical Oncology Pharmacist

Session Description:

Data-driven and patient-centered adverse effect management strategies for select anticancer therapies used in the treatment of patients with metastatic breast cancer will be discussed. This session will focus on CDK4/6 inhibitor-induced hepatotoxicity, prophylaxis of oral stomatitis with datopotamab deruxtecan, trastuzumab deruxtecan-related interstitial lung disease, and hyperglycemia with PI3K/AKT inhibitors. Presented as 4 patient cases, this presentation will gauge the audience's clinical practice followed by a review of current evidence and integration of the patient's perspective on toxicities and strategies to manage adverse effects.

Learning Objectives:

1. Create a monitoring and treatment for CDK4/6 inhibitor-induced hepatotoxicity
2. Discuss counseling points for stomatitis prevention and treatment with datopotamab deruxtecan
3. Apply data to customize a treatment and supportive care plan for interstitial lung disease from trastuzumab deruxtecan
4. Summarize the monitoring and treatment of hyperglycemia associated with PI3K inhibitors
5. Understand financial and time toxicities of supportive care management of breast cancer patients

UAN#: 0465-0000-26-063-H01-P

Presenter:

• Courtney Cavalieri, PharmD, BCOP - Clinical Oncology Pharmacist

Session Description:

Endocrine tumors are a rare and heterogeneous group of malignancies, ranging from relatively indolent to highly aggressive. Because of their rarity, treatment advances have historically been limited. However, within the last year, the FDA approved two new therapies: cabozantinib for neuroendocrine tumors and belzutifan for pheochromocytomas and paragangliomas. This session will review the data supporting these approvals and place them in the context of the broader treatment landscape for patients with endocrine malignancies.

Learning Objectives:

1. Understand the current treatment landscape for the spectrum of endocrine tumors
2. Evaluate the clinical trial data supporting the use of cabozantinib and belzutifan in the treatment of patients with various endocrine tumors

UAN#: 0465-0000-26-065-H01-P

Presenter:

• Christine Barrett, PharmD, BCOP - Oncology Pharmacy Specialist

Session Description:

Cutaneous squamous cell carcinoma (cSCC) is the second most common type of non-melanoma skin cancer, accounting for approximately 25% of all skin cancers. While most patients present with early-stage disease that is cured with surgical resection alone, a subset of patients develop high-risk locoregionally advanced or metastatic disease associated with substantial morbidity and mortality. In recent years, immunotherapy has dramatically changed the treatment landscape for cSCC, addressing an unmet need to continue to improve outcomes in patients with advanced cSCC. This continuing education session will review new and emerging therapies in patients with cSCC, including a review of the evolving role of immunotherapy and novel treatment strategies.

Learning Objectives:

1. Describe the evolving role of immunotherapy and epidermal growth factor receptor inhibitors in cutaneous squamous cell carcinoma
2. Summarize ongoing clinical trials and future areas of interest in cutaneous squamous cell carcinoma

UAN#: 0465-0000-26-067-H01-P

Presenters:

• Colleen McCabe, PharmD, BCOP - Clinical Pharmacist Oncology Specialist
• Lindsay Mundy, PharmD, BCOP - Clinical Pharmacist Specialist, Head & Neck Cancer

Session Description:

This breakout session will examine the emerging and controversial role of GLP-1 receptor agonists (GLP-1RAs). Two expert oncology pharmacists will review current evidence on GLP-1RAs related to cancer risk, including data suggesting potential risk reduction, risk increase, or neutral associations in specific malignancies. Discussion will also address clinical considerations for using GLP-1RAs in patients actively receiving cancer treatment, including overlapping toxicities such as nausea, vomiting, delayed gastric emptying, and potential impacts on treatment tolerance and nutritional status. Through case-based scenarios and shared decision-making frameworks, attendees will leave with practical strategies for evaluating GLP-1RA therapy in patients with cancer or at risk for cancer.

Learning Objectives:

1. Describe the current evidence regarding the oncologic risks and benefits of GLP-1RAs
2. Apply shared decision-making principles to the use of GLP-1RAs in oncology patients

UAN#: 0465-0000-26-069-H01-P

Presenter:

• Rachel McDevitt, PharmD, BCOP - Clinical Pharmacist Specialist

Session Description:

This session will begin with a brief background on sarcomas, highlighting some of the common subtypes and mainstays of treatment. Then, new literature including doxorubicin + trabectedin followed by trabectedin maintenance for leiomyosarcoma and nirogacestat for desmoid tumors will be discussed. Key trials for each of these therapies will be presented and analyzed, and discussion will include pearls for managing patients receiving these therapies. The session will conclude with practical pearls for administering sarcoma therapies, including high-dose methotrexate in the outpatient setting.

Learning Objectives:

1. Describe recent clinical trial data supporting emerging therapies for select sarcoma subtypes
2. Apply practical management strategies for administering sarcoma therapies including high-dose methotrexate in the outpatient setting

UAN#: 0465-0000-26-071-H99-P

Presenter:

• Karen Fancher, PharmD, BCOP - Associate Professor of Pharmacy Practice

Session Description:

Ethical dilemmas in oncology pharmacy can be particularly complex due to the overlap of pharmacological and medical factors with patient and caregiver beliefs and values, as well as with the pharmacist's professional and moral responsibilities. Such situations have no right or wrong answer and are often challenging scenarios that require careful consideration to resolve. This interactive audience discussion will center on an ethical dilemma commonly encountered in oncology pharmacy practice. The audience will be encouraged to ask questions or request more information about the patient's situation, and possible solutions will be proposed. The presentation will demonstrate the application of ethical principles by oncology pharmacists to assist in determining the most appropriate solutions in such situations.

Learning Objectives:

1. Define the fundamental ethical principles that frequently occur in oncology pharmacy practice
2. Review the process of making an ethical decision using an example patient case

UAN#: 0465-0000-26-073-H01-P

Presenter:

• Matthew Warrick, PharmD, BCOP, BCPS - Clinical Pharmacy Specialist

Session Description:

Novel treatment options have emerged for patients with relapsed/refractory diffuse large B-cell lymphoma in the form of bispecific CD20-directed CD3 T-cell engagers. The efficacy of these agents as salvage monotherapy has led to their earlier incorporation as a backbone in combination with salvage chemotherapy or immunotherapy for patients ineligible for ASCT or unfit for CAR-T. This presentation will discuss recent data investigating the use of BsAb-based combination regimens in the R/R setting. In addition, this session will attempt to highlight optimal sequencing of BsAb-based combinations in the second line and the possible therapeutic benefits over traditional chemoimmunotherapy as bridge to ASCT or CAR-T, including patients who may have previously been unfit for cellular therapy.

Learning Objectives:

1. Discuss recent clinical trial data investigating the use of bispecific antibodies (BsAbs) in combination with chemotherapy or immunotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
2. Evaluate the place in therapy for discussed therapeutic agents, including clinical considerations that influence sequencing of BsAb-containing regimens in the R/R DLBCL setting

UAN#: 0465-0000-26-078-H01-P

Hybrid Observation Model for Bispecific T-Cell Engager Tarlatamab (HOME)

Presenter:

• Alyssa Cendagorta, PharmD, BCOP - Hematology Oncology Clinical Pharmacy Specialist

Session Description:

Risks associated with the bispecific T-cell engager tarlatamab include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Given that the CRS experienced with tarlatamab has been characterized as mostly grade 1 and 2 in nature, out institution implemented a hybrid observation model starting August 2024. Tarlatamab was infused outpatient and patients were subsequently observed in the inpatient unit for CRS and ICANS monitoring and management. The aim of this retrospective chart review is to characterize our institutions experience using a hybrid oncology administration model for tarlatamab including patient demographics, safety outcomes, and length of stay information.

Learning Objective:

1. Describe the hybrid oncology model utilized for administration of the bispecific T-cell engager, tarlatamab

Safety of Shortened Post-Infusion Observation Times for Pertuzumab and Ado-Trastuzumab Emtansine: A Retrospective and Prospective Analysis

Presenter:

• Jennifer Hutchinson, PharmD, BCOP - Oncology Clinical Pharmacy Specialist

Session Description:

The incidence of infusion-related reactions (IRR) for pertuzumab and ado-trastuzumab emtansine (T-DM1) reported in clinical trials is significantly lower than that of trastuzumab (40%), at 21% and 1.6%, respectively. Despite these lower rates, FDA-recommended post-infusion observation times remain prolonged. Limited real-world data exist on IRR characterization and the safety of reduced observation times, potentially leading to unnecessary monitoring and extended chair time. This session will explore the real-world incidence of IRR for pertuzumab and T-DM1 at our cancer institute, assess the safety of implementing reduced observation times, and discuss how these findings can support reevaluation of current observation times to guide future practice standards.

Learning Objective:

1. Discuss the real-world rates of infusion-related reactions (IRR) in patients receiving pertuzumab or ado-trastuzumab emtansine for the treatment of breast cancer

From Diagnosis to Decision-Making: Black Patient and Caregiver Perspectives on Lung Cancer Care and Support Needs

Presenter:

• Shanada Monestime, PharmD, BCOP - Director, Community Engaged Research

Session Description:

Despite advances in lung cancer treatment, gaps in communication and navigation continue to limit equitable access to biomarker testing, clinical trials, and supportive care. This session examines how these gaps shape patient and caregiver experiences across diagnosis and treatment, drawing on insights from community-based interviews in high-disparity regions. The session highlights where breakdowns occur, why patient priorities are often missed, and how care teams can better support understanding and engagement. Emphasis is placed on the role of pharmacists and pharmacy teams in reinforcing education, supporting navigation, and contributing to more patient-centered, equitable lung cancer care.

Learning Objective:

1. Upon completion, learners will be able to describe how communication gaps and support needs influence Black patients' and caregivers' understanding of biomarker tresting, clinical trials, and navigation across the lung cancer care continuum

CMV Reactivation with Bispecific Antibodies in Multiple Myeloma

Presenter:

• Jordan Snyder, PharmD, BCOP - Clinical Hematology Pharmacist

Session Description:

Bispecific antibodies have changed the treatment landscape in multiple myeloma in both late and early relapse. However, their use is associated with increased risk of infections, including CMV reactivation, which may lead to treatment interruption or discontinuation. In this session, we will review data from seven academic medical centers and evaluate incidence and risk factors for CMV reactivation in patients receiving bispecific antibodies for relapsed/refractory multiple myeloma.

Learning Objective:

1. Describe incidence and risk factors for CMV reactivation in patients receiving bispecific antibodies for multiple myeloma

UAN#: 0465-0000-26-053-H01-P

Presenters:

• Natalie Brumwell, PharmD, BCOP - Clinical Pharmacy Specialist
• Jamie Marchesseault (Brown), PharmD, BCOP - Clinical Pharmacy Specialist
• Mary McGann, PharmD, BCOP - Pharmacy Clinical Specialist

Session Description:

As the use of CAR-T cell therapy expands, clinicians are increasingly challenged by the unique and evolving infectious complications that follow treatment. This BCOP CE session will explore the pathophysiology, epidemiology, prevention, and management strategies for infections post-CAR T, with a focus on optimizing patient outcomes through evidence-based management and education.

Learning Objectives:

1. Describe the pathophysiologic mechanisms and immunologic changes that predispose patients to infections following CAR-T cell therapy
2. Review the incidence and timing for bacterial, viral, and funal infections in patients receiving CAR-T cell therapy
3. Develop individualized antimicrobial prophlaxis and infection monitoring strategies for patients receiving CAR-T cell therapy
4. Apply evidence-based approaches for managing infectious complications after CAR-T cell therapy
5. Evaluate vaccination strategies after CAR-T cell therapy

UAN#: 0465-0000-26-059-H01-P

Presenter:

• Leila Rostamnjad, PharmD, BCOP - Clinical Pharmacy Manager & Clinical Pharmacy Specialist, Thoracic Oncology and SYmptoms Management

Session Description:

As the treatment landscape for non-small cell lung cancer (NSCLC) continues to expand, this session will highlight key advances beyond EGFR and ALK. Topics include the role of taletrectinib in ROS1-rearranged NSCLC, the use of zenocutuzumab for NRG1 fusion positive disease, and integration of telisotuzumab vedotin for c-MET overexpression. Emerging data on HER2-targeted therapies, trastuzumab deruxtecan, zongertinib, and sevabertinib in HER2 mutant NSCLC will also be reviewed, with emphasis on clinical efficacy, safety, and treatment sequencing.

Learning Objectives:

1. Describe the role of taletrectinib in the treatment of ROS1-rearranged NSCLC
2. Apply recently approved zenocutuzumab in the treatment of NSCLC with NRG1 fusion
3. Integrate telisotuzumab vedotin into therapeutic decisions for NSCLC patients with c-MET overexpression
4. Review clinical data evaluating the use of trastuzumab deruxtecan, zongertinib, and sevabertinib in the treatment of HER2-mutation-positive NSCLC

UAN#: 0465-0000-26-061-H01-P

Presenter:

• Grace Baek, PharmD, BCOP - Clinical Oncology Pharmacist

Session Description:

The therapeutic armamentarium of mantle cell lymphoma (MCL) has rapidly expanded in the past few years to include targeted therapies, creating new opportunities for pharmacists to apply their expertise in evaluating efficacy, safety, and optimal use of these novel agents in clinical practice. This session will present significant updates in the management of treatment-naive MCL, with a focus on the implementation and evolving role of Bruton's tyrosine kinase (BTK) inhibitors in this setting. Additionally, this presentation will discuss advances in the treatment of relapsed/refractory MCL with novel agents such as chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies, and non-covalent BTK inhibitors, including a review of key efficacy outcomes, strategies for adverse event management, and considerations for treatment sequencing.

Learning Objectives:

1. Discuss the frontline use of Bruton's tyrosine kinase inhibitors (BTKis) in mantle cell lymphoma
2. Apply patient-specific factors to construct BTKi-based therapeutic plans for individuals with treatment-based therapeutic plans for individuals with treatment-naive MCL
3. Evaluate efficacy outcomes and toxicity management strategies for regimens incorporating pirtobrutinib, glofitamab, and/or chimeric antigen receptor T-cell therapy (CAR-T) for treatment of relapsed/refractory MCL
4. Formulate sequencing strategies for pirobrutinib, glofitamab, and CAR-T therapy in relapsed/refractory MCL based on disease characteristics, prior therapy, and available clinical data